Article Text
Therapeutics/Prevention
Randomised controlled trial
Long-term ticagrelor therapy in patients with prior myocardial infarction significantly reduces ischaemic events, albeit with increased bleeding
Statistics from Altmetric.com
Footnotes
Competing interests DA has received speaker honoraria from AstraZeneca and advisory board fees from AstraZeneca, Boeringer Ingelheim, Bayer and the Medicines Company.
Provenance and peer review Commissioned; internally peer reviewed.